No abstract available.
Drug Therapy*

Herpes zoster is a viral infection of the dorsal nerve root causing painful vesicular eruptions over the skin or mucous membrane of the affected nerve. It is less well known to the dermatologists that berpes zoster causcs bladder dysfunction when the zoster affects the lumbar and sacral spinal ganglia. The authors observed a case of herpes zoster involving the S 2~4 dermatomes, associated with bladder atony in a 58 year old male who had received rad.iotherapy and chemotherapy for his malignant Iymphoma of lymphocytic type. Conservative treatment with urinary catheterization and antibiotics resulted in complete recovery of the bladder function about 3 weeks later. He had also ichthyosiform skin lesions on his back and lower extremities which, by carefuI history and histopathological examination, proved to be acquired ichthyosis.
Anti-Bacterial Agents ; Drug Therapy ; Ganglia, Spinal ; Herpes Zoster* ; Humans ; Ichthyosis* ; Lower Extremity ; Lymphoma* ; Male ; Middle Aged ; Mucous Membrane ; Skin ; Urinary Bladder ; Urinary Bladder, Neurogenic* ; Urinary Catheterization ; Urinary Catheters

No abstract available.
Autoantibodies* ; Incidence* ; Interferon-gamma*

No abstract available.
Blood Platelets* ; Humans* ; Membranes* ; Plasminogen*

No abstract available.
Granulocyte-Macrophage Colony-Stimulating Factor* ; Granulocytes* ; Humans* ; Macrophages* ; Methotrexate*

No abstract available.
Colorectal Neoplasms* ; Fluorouracil* ; Humans ; Interferon-gamma*

No abstract available.
Bone Marrow Transplantation* ; Bone Marrow* ; Erythroid Precursor Cells* ; Pathology*

A total of 47 patients with a diagnosis of nasopharyngeal carcinoma was treated in Department of Therapeutic Radiology, Seoul National University Hospital during last 4 years. Of the 47 patients, 23(49%) had undifferentiated carcinoma, 20(43%) had squamous cell carcinoma, while 4(8%) had lymphoepithelioma. Most of the patients(71%) has Stage IV disease, cervical lymph node metastases were found in 36(77%) and distant metastasis was found in 1 at the time of diagnosis. Complete response rate after radiotherapy for 47 patients of nasopharyngeal carcinoma was 85.1%. The overall actuarial 3 year survival rates was 0.718 and the disease free actuarial 3 year survival rates was 0.468. Nodal involvement and symptom duration were statistically significiant influencing factors for actuarial survival rate. Treatment failures were found in 20 patients (42.6%), local recurrence only in 6(30%), local and neck recurrence in 3(15%), local recurrence with metastasis in 4(20%) and distant metastasis only in 7(35%). Local failures were more frequent in the patients with cranial nerve symptoms (P=0.032). Distant metastases were more frequent with T4 lesions (P=0.047), and with nodal involvement (P<0.01). Retreatment after the tumor recurrence was chemotherapy and/or radiotherapy, two patients refreated for local recurrence were alive without evidence of disease for more than 19 and 44 months after retreatment.
Carcinoma ; Carcinoma, Squamous Cell ; Cranial Nerves ; Diagnosis ; Drug Therapy ; Humans ; Lymph Nodes ; Neck ; Neoplasm Metastasis ; Radiation Oncology ; Radiotherapy* ; Recurrence ; Retreatment ; Seoul ; Survival Rate ; Treatment Failure

No abstract available.
Leukemia*

PURPOSE: We investigated the effectiveness and safety of DA-3030 for prophylatic use in patients receiving chemotherapy for malignant disease. MATERIALS AND METHODS: Seventy cancer patients were randomized to receive chemotherapy alone (36 patients) or with DA-3030 administered (34 patients) after stratified block randomization according to chemotherapeutic regimen. DA-3030 was subcutaneously administered at the dose of 100 pg/m/day for 10 days from 24 hours after the completion of chemotherapy. RESULTS: Of the 70 enrolled patients, 62 patients were evaluable. The neutropenia (absolute neutrophil count [ANC] <1,000/mm) occurred in 9 of 32 (28.1%) of the DA-3030 group and 21 of 30 (90.0%) of the control group, giving relative risk for control group of 0.154 (95% confidence interval [CI], 0.05 to 0.45; p-0.0001). Severe neutropenia (ANC 500/mm') occurred in 4 of 32 (12.5%) of the DA-3030 group and in 20 of 30 (66.7%) of the control group (relative risk for control group of 0.316 [95% CI, 0,18 to 0.55]; p=0.0001). The mean duration of neutropenic period (+/-standard error) was 1.13+/-0.34 days in the DA-3030 group and 6.73+/-0.69 days in the control group respectively, and was significantly shorter in the DA-3030 group (p<0.0001). And, there was higher nadir ANC in the OA-3030 group than that in the control group (p=0.0001); the mean nadir ANC was 2,547+/- 343/mm and 442+/-120/mm, respectively. The DA-3030 group had significantly higher incidence of myalgia in comparison to the control group (43.8% compared with 3.3%; p=0.001). However, it was tolerable and was easily managed by conservative therapy CONCLUSION: The use of DA-3030 was effective in preventing chemotherapy-induced neutropenia.
Drug Therapy* ; Humans ; Incidence ; Myalgia ; Neutropenia* ; Neutrophils ; Random Allocation